The company made the announcement during its capital markets day in Frankfort this week.
Fresenius said that the goal of $26.9 billion represents an annual average growth rate of approximately 10%, during which the company hopes it will see a high single-digit percent increase in its net income.
The company said that it was driving towards the goals by developing its core business, and said it plans to continue growth of its care coordination business which includes hospital services that “provide a holistic approach in healthcare for the company’s patients.”
Fresenius said it plans to launch a new efficiency program, dubbed the global efficiency program II, which looks to “identify and realize further efficiency potential and enhance the overall competitiveness of Fresenius Medical Care.”
The program aims to reduce spending by between $112 million and $224 million (EU €100 million – €200 million).
“The number of dialysis patients is expected to increase from 3 million at the end of 2016 to approximately 4.9 million by 2025. By leveraging our strong core competencies as the leading integrated global provider in the dialysis industry and more than a decade of experience in value-based care, we are excellently positioned for further profitable growth,” CEO Rice Powell said in prepared remarks.
In May, Fresenius saw shares rise after the medical device maker met expectations on Wall Street with its 1st quarter earnings results.
The Bad Homburg, Germany-based company posted profits of $273.2 million, or 53¢ per share, on sales of $4.8 billion for the 3 months ended March 31, for bottom-line growth of 16.9% while sales grew 13.6% compared with the same period in the previous year.